Top

Published in:

01-08-2020 | Anesthetics | Narrative Review

Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS

Authors: Angela Jerath, Niall D. Ferguson, Brian Cuthbertson

Published in: Intensive Care Medicine | Issue 8/2020

Abstract

Hospitals worldwide are experiencing a shortage in essential intravenous sedative medications. This is attributable to high number and high sedative needs of COVID-19 critical care patients with disruption of drug supply chains. Inhaled volatile anesthetic agents are an abundant resource and readily implementable solution for providing ICU sedation. Inhaled volatile agents may also provide important pulmonary benefits for COVID-19 patients with ARDS that could improve gas exchange and reduce time spent on a ventilator. We review the use of volatile agents, and provide a technical overview and algorithm for administering inhaled volatile-based sedation in ICUs.

FDA Drug shortages (2020) Book FDA Drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm. Accessed 14 Apr 2020.

Government of Canada (2020) Exceptional importation and sale of drugs in relation to COVID-19: tier 3 drug shortages. https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/covid19-interim-order-drugs-medical-devices-special-foods/information-provisions-related-drugs-biocides/tier-3-shortages.html. Accessed 13 Apr 2020.

Jabaudon M, Boucher P, Imhoff E, Chabanne R, Faure JS, Roszyk L, Thibault S, Blondonnet R, Clairefond G, Guerin R, Perbet S, Cayot S, Godet T, Pereira B, Sapin V, Bazin JE, Futier E, Constantin JM (2017) Sevoflurane for sedation in acute respiratory distress syndrome. A randomized controlled pilot study. Am J Respir Crit Care Med 195:792–800CrossRef

De Conno E, Steurer MP, Wittlinger M, Zalunardo MP, Weder W, Schneiter D, Schimmer RC, Klaghofer R, Neff TA, Schmid ER, Spahn DR, Z'Graggen BR, Urner M, Beck-Schimmer B (2009) Anesthetic-induced improvement of the inflammatory response to one-lung ventilation. Anesthesiology 110:1316–1326CrossRef

Ferrando C, Aguilar G, Piqueras L, Soro M, Moreno J, Belda FJ (2013) Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study. Eur J Anaesthesiol 30:455–463CrossRef

Jerath A, Parotto M, Wasowicz M, Ferguson ND (2016) Volatile anesthetics. is a new player emerging in critical care sedation? Am J Respir Crit Care Med 193:1202–1212CrossRef

Jerath A, Beattie SW, Chandy T, Karski J, Djaiani G, Rao V, Yau T, Wasowicz M (2015) Volatile-based short-term sedation in cardiac surgical patients: a prospective randomized controlled trial. Crit Care Med 43:1062–1069CrossRef

Jerath A, Panckhurst J, Parotto M, Lightfoot N, Wasowicz M, Ferguson ND, Steel A, Beattie WS (2017) Safety and efficacy of volatile anesthetic agents compared with standard intravenous midazolam/propofol sedation in ventilated critical care patients: a meta-analysis and systematic review of prospective trials. Anesth Analg 124:1190–1199CrossRef

Wong K, Wasowicz M, Grewal D, Fowler T, Ng M, Ferguson ND, Steel A, Jerath A (2016) Efficacy of a simple scavenging system for long-term critical care sedation using volatile agent-based anesthesia. Can J Anaesth 63:630–632CrossRef

10.

Jerath A, Steel A, Ferguson N, Wasowicz M (2016) High fluoride levels with isoflurane critical care sedation does not cause nephrotoxicity. Am J Respir Crit Care Med 193:A3639CrossRef

11.

Maussion E, Combaz S, Cuisiner A, Chapuis C, Payen JF (2019) Renal dysfunction during sevoflurane sedation in the ICU. Eur J Anaesthesiol 36:375–385CrossRef

12.

Chabanne R, Perbet S, Futier E, Ait Ben Said N, Jaber S, Bazin JE, Pereira B, Constantin JM (2014) Impact of the Anesthesia Conserving Device on respiratory parameters and work of breathing in critically ill patients under light sedation with sevoflurane. Anesthesiology 121:808–816CrossRef

13.

Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L (2020) COVID-19 pneumonia: different respiratory treatment for different phenotypes? Intensive Care Med. https://doi.org/10.1007/s00134-020-06033-2 CrossRefPubMedPubMedCentral

14.

Liu X, Liu X, Xu Y, Xu Z, Huang Y, Chen S, Li S, Liu D (2020) Ventilatory ratio in hypercapnic mechanically ventilated patients with COVID-19 associated ARDS. Am J Respir Crit Care Med 201(10):1297–1299CrossRef

15.

Meiser A, Bomberg H, Lepper PM, Trudzinski FC, Volk T, Groesdonk HV (2017) Inhaled sedation in patients with acute respiratory distress syndrome undergoing extracorporeal membrane oxygenation. Anesth Analg 125:1235–1239CrossRef

Title: Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS
Authors: Angela Jerath
Niall D. Ferguson
Brian Cuthbertson
Publication date: 01-08-2020
Publisher: Springer Berlin Heidelberg
Keywords: Anesthetics
Acute Respiratory Distress-Syndrome
COVID-19
Sevoflurane
Anesthetics
Isoflurane
Published in: Intensive Care Medicine / Issue 8/2020
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-020-06154-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

Ten things we learned about COVID-19

Rapidly scalable mechanical ventilator for the COVID-19 pandemic

Might the surviving sepsis campaign international guidelines be less confusing? Authors’ reply

ICU capacity management during the COVID-19 pandemic using a process simulation

Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis

Clinical features and development of sepsis in patients infected with SARS-CoV-2: a retrospective analysis of 150 cases outside Wuhan, China